FCSC Fibrocell Science Inc.

2.99
0  0%
Previous Close 2.99
Open 2.99
Price To Book 2.72
Market Cap 29,177,413
Shares 9,758,332
Volume 116,103
Short Ratio
Av. Daily Volume 61,917
Stock charts supplied by TradingView

NewsSee all news

  1. Intrexon Reports Third Quarter 2019 Financial Results

    GERMANTOWN, Md., Nov. 12, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its

  2. Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of SRC Energy, Pivotal Software, MAM Software Group, and Fibrocell Science on behalf of Stockholders and Encourages Investors to Contact the Firm

    NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of SRC Energy Inc. (NYSE:SRCI), Pivotal Software,

  3. Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – UCFC, SEMG, ALDR, FCSC

    NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: United Community Financial Corp. (NASDAQ:UCFC)The investigation

  4. Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Fibrocell Science, Inc. (NASDAQ: FCSC) on Behalf of Fibrocell Shareholders and Encourages Fibrocell Investors to Contact the Firm

    NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Fibrocell Science, Inc. (NASDAQ:FCSC) on behalf of Fibrocell shareholders

  5. FIBROCELL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fibrocell Science, Inc. - FCSC

    Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Fibrocell Science, Inc. (NASDAQ:FCSC) to Castle Creek

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

CRL issued December 18, 2009. Approved June 22, 2011.
Laviv
Wrinkles
Phase 2 endpoints not met - June 2016
azficel-T
Chronic Dysphonia
Phase 3 data due 4Q 2020.
FCX-007 - DEFI-RDEB
Recessive dystrophic epidermolysis bullosa
Phase 1 part of trial to complete enrolment 3Q 2019. Data due mid-2020.
FCX-013
Scleroderma

Latest News

  1. Intrexon Reports Third Quarter 2019 Financial Results

    GERMANTOWN, Md., Nov. 12, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced its

  2. Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of SRC Energy, Pivotal Software, MAM Software Group, and Fibrocell Science on behalf of Stockholders and Encourages Investors to Contact the Firm

    NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of SRC Energy Inc. (NYSE:SRCI), Pivotal Software,

  3. Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – UCFC, SEMG, ALDR, FCSC

    NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: United Community Financial Corp. (NASDAQ:UCFC)The investigation

  4. Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Fibrocell Science, Inc. (NASDAQ: FCSC) on Behalf of Fibrocell Shareholders and Encourages Fibrocell Investors to Contact the Firm

    NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Fibrocell Science, Inc. (NASDAQ:FCSC) on behalf of Fibrocell shareholders

  5. FIBROCELL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fibrocell Science, Inc. - FCSC

    Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Fibrocell Science, Inc. (NASDAQ:FCSC) to Castle Creek

  6. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Fibrocell Science, Inc. to Castle Creek Pharmaceutical Holdings, Inc. is Fair to Shareholders

    NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Fibrocell Science, Inc. ("Fibrocell" or the "Company")

  7. Due to Rising Prevalence of Cancer in U.S., Cancer Therapy Market Showing Rapid Growth

    PALM BEACH, Florida, Sept. 16, 2019 /PRNewswire/ -- The global cancer therapy market looks like it will continue trend to continue its growth, worldwide. Cancer therapies are drugs that block the growth and proliferation

  8. Castle Creek Pharmaceutical Holdings Announces Agreement to Acquire Fibrocell

    PARSIPPANY, N.J., Sept. 12, 2019 /PRNewswire/ -- Castle Creek Pharmaceutical Holdings, Inc. ("CCP Holdings") today announced it has reached an agreement to acquire Fibrocell Science, Inc. (NASDAQ:FCSC), a cell

  9. Castle Creek Pharmaceutical Holdings to Acquire Fibrocell

    - Total consideration of $63.3 million, including repayment of debt and other financial instruments - - Acquisition expected to close in the fourth quarter of 2019 - - Further strengthens Castle Creek Pharmaceuticals